Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BGNE |
---|---|---|
09:32 ET | 3099 | 192.9 |
09:39 ET | 400 | 193.035 |
09:41 ET | 100 | 192.28 |
09:50 ET | 100 | 191.4 |
09:52 ET | 109 | 191.3779 |
09:56 ET | 566 | 190.9361 |
09:57 ET | 100 | 190.97 |
09:59 ET | 100 | 191.695 |
10:03 ET | 200 | 190.78 |
10:06 ET | 200 | 190.6 |
10:08 ET | 234 | 190.38 |
10:10 ET | 684 | 190.47 |
10:12 ET | 26200 | 190.46 |
10:14 ET | 100 | 191.12 |
10:15 ET | 200 | 190.715 |
10:17 ET | 100 | 190.66 |
10:19 ET | 100 | 190.08 |
10:21 ET | 193 | 190.51 |
10:24 ET | 200 | 190.58 |
10:26 ET | 200 | 190.9 |
10:28 ET | 190 | 191.18 |
10:30 ET | 300 | 191.15 |
10:32 ET | 300 | 191.095 |
10:33 ET | 200 | 191.27 |
10:35 ET | 900 | 190.23 |
10:37 ET | 408 | 189.9 |
10:46 ET | 300 | 189.54 |
10:51 ET | 100 | 189.31 |
10:57 ET | 600 | 189.265 |
11:00 ET | 200 | 188.86 |
11:02 ET | 200 | 189.32 |
11:09 ET | 300 | 189.15 |
11:15 ET | 272 | 189.105 |
11:24 ET | 295 | 189 |
11:26 ET | 2800 | 188.66 |
11:27 ET | 1027 | 188.61 |
11:38 ET | 1200 | 188.79 |
11:42 ET | 100 | 189.075 |
11:45 ET | 200 | 188.87 |
11:47 ET | 200 | 188.855 |
11:51 ET | 1200 | 188.61 |
11:56 ET | 100 | 188.75 |
11:58 ET | 100 | 188.99 |
12:00 ET | 300 | 189.11 |
12:02 ET | 400 | 188.79 |
12:03 ET | 200 | 188.92 |
12:09 ET | 700 | 189.065 |
12:12 ET | 200 | 189.14 |
12:21 ET | 100 | 189.28 |
12:30 ET | 400 | 189.235 |
12:39 ET | 100 | 189.4 |
12:41 ET | 100 | 189.55 |
12:50 ET | 300 | 189.53 |
12:52 ET | 462 | 189.3654 |
12:56 ET | 100 | 189.3 |
12:57 ET | 100 | 189.51 |
01:03 ET | 388 | 189.4004 |
01:10 ET | 600 | 190.385 |
01:14 ET | 100 | 190.605 |
01:15 ET | 109 | 190.64 |
01:17 ET | 300 | 191.2 |
01:19 ET | 100 | 191.01 |
01:21 ET | 200 | 191.36 |
01:24 ET | 100 | 191.38 |
01:30 ET | 200 | 191.285 |
01:33 ET | 100 | 191.56 |
01:37 ET | 100 | 191.59 |
01:42 ET | 100 | 191.57 |
01:44 ET | 218 | 191.29 |
01:46 ET | 649 | 191.715 |
01:48 ET | 200 | 191.74 |
01:50 ET | 100 | 191.84 |
01:53 ET | 600 | 191.8 |
01:55 ET | 2280 | 192.54 |
02:00 ET | 200 | 192.375 |
02:02 ET | 100 | 192.59 |
02:04 ET | 800 | 192.215 |
02:06 ET | 100 | 191.93 |
02:08 ET | 300 | 192.04 |
02:20 ET | 300 | 192.415 |
02:26 ET | 200 | 192.105 |
02:36 ET | 961 | 191.675 |
02:42 ET | 400 | 191.77 |
02:45 ET | 132 | 191.7507 |
02:49 ET | 200 | 191.94 |
02:56 ET | 100 | 191.95 |
02:58 ET | 400 | 191.92 |
03:02 ET | 200 | 191.895 |
03:07 ET | 100 | 191.99 |
03:12 ET | 483 | 191.88 |
03:14 ET | 100 | 192.11 |
03:16 ET | 100 | 192.04 |
03:20 ET | 600 | 191.83 |
03:21 ET | 200 | 191.885 |
03:27 ET | 100 | 192.115 |
03:30 ET | 100 | 192.34 |
03:34 ET | 200 | 192.1 |
03:36 ET | 100 | 192.075 |
03:38 ET | 656 | 192.01 |
03:39 ET | 400 | 191.85 |
03:41 ET | 200 | 191.73 |
03:43 ET | 100 | 191.9 |
03:45 ET | 1703 | 191.81 |
03:48 ET | 456 | 191.88 |
03:50 ET | 100 | 192.035 |
03:52 ET | 1100 | 191.95 |
03:54 ET | 1008 | 191.68 |
03:56 ET | 2401 | 191.76 |
03:57 ET | 200 | 191.86 |
03:59 ET | 15491 | 191.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Beigene Ltd | 21.0B | -37.7x | --- |
Biomarin Pharmaceutical Inc | 16.0B | 63.4x | --- |
United Therapeutics Corp | 15.4B | 15.9x | +8.22% |
Exact Sciences Corp | 10.9B | -61.5x | --- |
Neurocrine Biosciences Inc | 12.1B | 36.3x | +62.04% |
Qiagen NV | 10.0B | 139.8x | +12.66% |
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.0B |
---|---|
Revenue (TTM) | $3.1B |
Shares Outstanding | 106.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-5.08 |
Book Value | $36.95 |
P/E Ratio | -37.7x |
Price/Sales (TTM) | 6.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.